Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Immatics N.V is a biotechnology business based in the US. Immatics N-V shares (IMTX) are listed on the NASDAQ and all prices are listed in US Dollars. Immatics N-V employs 331 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $10.50 |
|---|---|
| 52-week range | $10.12 - $18.42 |
| 50-day moving average | $11.96 |
| 200-day moving average | $12.32 |
| Wall St. target price | $25.45 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.04 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $10.5 from 2022-01-21
| 1 week (2022-01-14) | -11.54% |
|---|---|
| 1 month (2021-12-23) | -18.98% |
| 3 months (2021-10-22) | -19.23% |
| 6 months (2021-07-23) | -14.00% |
| 1 year (2021-01-22) | -6.08% |
|---|---|
| 2 years (2020-01-20) | N/A |
| 3 years (2019-01-20) | N/A |
| 5 years (2017-01-20) | N/A |
| Revenue TTM | $28.5 million |
|---|---|
| Gross profit TTM | $-35,832,000 |
| Return on assets TTM | -23.41% |
| Return on equity TTM | -143.21% |
| Profit margin | 0% |
| Book value | $0.56 |
| Market capitalisation | $746.7 million |
TTM: trailing 12 months
We're not expecting Immatics N-V to pay a dividend over the next 12 months.
Over the last 12 months, Immatics N-V's shares have ranged in value from as little as $10.12 up to $18.42. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Immatics N-V's is 0.1574. This would suggest that Immatics N-V's shares are less volatile than average (for this exchange).
Immatics N. V. , a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, an anti-tumor therapy, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies includes IMA401, a cancer testis antigen for the treatment of solid tumor; and IMA402 for the treatment of solid tumors. It also develops IMA101, a multi-target precision immunotherapy; and IMA301, an allogenic cellular therapy product candidate.
Cardano’s first metaverse project is available to investors now — if you can find a piece of digital land on sale. Plots sold fast despite the project’s early stage limitations.
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.